MetaVia reports Q2 2026 results, all patients reach top DA-1726 doses
MetaVia said patients in its Phase 1 Part 3 study of DA-1726 have reached the highest planned dose levels, with 16-week topline data expected in Q4 2026.
MetaVia Inc. (Nasdaq: MTVA) reported financial results for the quarter ended June 30, 2026, and gave a corporate update on August 6, 2026.
The company said all active patients in both cohorts of its ongoing Phase 1 Part 3 study of DA-1726 have reached the highest planned dose levels of 48 mg and 64 mg, which it called an important execution milestone ahead of its 16-week topline data readout expected in the fourth quarter of 2026.1 CEO Hyung Heon Kim noted that data from the 48 mg Phase 1 study presented at the EASL and ADA conferences showed up to 9.1% mean weight loss after eight weeks of treatment, along with reductions in waist circumference and findings related to liver measures, which the company said supported DA-1726's potential.1
On the vanoglipel (DA-1241) program for MASH, MetaVia said it is working to schedule a meeting with the FDA marking the end of Phase 2, during the second half of 2026, to discuss next steps in clinical development for the combination therapy.1
Financially, R&D expenses were approximately $3.5 million for the second quarter, up from approximately $2.3 million a year earlier.1 G&A expenses were approximately $1.9 million, down slightly from approximately $2.0 million a year earlier.1 Net loss was $5.3 million, or $0.90 per share, compared with a net loss of $4.0 million, or $2.87 per share, in the second quarter of 2025.1
Cash and cash equivalents totaled $12.6 million as of June 30, 2026, up from $10.3 million at the end of 2025, and the company said it expects this to be adequate to fund operations through 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.